Onconic Therapeutics Company Description

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea.

It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields.

JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer.

The company was founded in 2020 and is based in Seoul, South Korea.

Onconic Therapeutics Inc.

Country	South Korea
Founded	2020
Industry	Biotechnology
Sector	Healthcare
CEO	John Kim

Contact Details

Address: 12 Teheranro-26-gil Seoul, 06236 South Korea
Phone	82 2 3454 0780
Website	onconic.co.kr

Stock Details

Ticker Symbol	476060
Exchange	KOSDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	KRW
ISIN Number	KR7476060009
SIC Code	2836

Key Executives

Name	Position
John Kim	Chief Executive Officer
Jongkil Shin	Chief Financial Officer